Yahoo · Aug 13, 2026
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript
MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.
CY
NASDAQ · CYTK
Cytokinetics, Incorporated
Healthcare · Biotechnology
$76.84
Down-$0.34 (-0.44%)
Updated Aug 22, 2026, 2:43 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.23B
- P/E ratio
- -9.7
- Dividend yield
- 0.00%
- 52-week range
- $35.22 – $88.31
- Volume
- 1.52M
- Avg. volume
- 2.02M
Price performance
CYTK price history
1M range · 21 trading sessions · Daily adjusted prices
CYTK closed at $76.84 after 21 trading sessions, down 4.83% for the selected period.
- Last close
- $76.84
- Period change
- -4.83%
- Period low
- $73.45
- Period high
- $81.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $77.30 | $77.70 | $76.65 | $76.84 | 1.52M |
| Aug 20, 2026 | $77.36 | $77.62 | $76.14 | $77.18 | 1.65M |
| Aug 19, 2026 | $77.23 | $77.88 | $76.17 | $77.74 | 1.51M |
| Aug 18, 2026 | $75.57 | $76.81 | $74.76 | $76.10 | 1.65M |
| Aug 17, 2026 | $73.90 | $75.92 | $73.46 | $75.87 | 1.49M |
| Aug 14, 2026 | $72.70 | $74.26 | $72.12 | $74.13 | 1.76M |
| Aug 13, 2026 | $76.80 | $76.81 | $73.40 | $73.45 | 1.77M |
| Aug 12, 2026 | $76.71 | $77.71 | $75.34 | $75.64 | 2.11M |
| Aug 11, 2026 | $78.65 | $78.95 | $76.30 | $76.45 | 1.27M |
| Aug 10, 2026 | $76.09 | $77.89 | $75.67 | $77.49 | 2.27M |
| Aug 7, 2026 | $81.23 | $81.50 | $75.87 | $76.76 | 3.6M |
| Aug 6, 2026 | $78.94 | $81.77 | $78.745 | $81.37 | 2.52M |
| Aug 5, 2026 | $79.42 | $80.49 | $77.70 | $78.85 | 1.59M |
| Aug 4, 2026 | $77.25 | $79.82 | $76.70 | $78.61 | 2.45M |
| Aug 3, 2026 | $76.69 | $77.165 | $74.89 | $76.45 | 2.24M |
| Jul 31, 2026 | $80.32 | $80.805 | $76.96 | $77.13 | 1.58M |
| Jul 30, 2026 | $78.39 | $80.844 | $77.90 | $80.42 | 2.09M |
| Jul 29, 2026 | $79.77 | $80.34 | $78.0732 | $78.385 | 1.78M |
| Jul 28, 2026 | $81.02 | $81.02 | $78.98 | $79.45 | 1.66M |
| Jul 27, 2026 | $81.51 | $82.4099 | $79.90 | $80.62 | 1.84M |
| Jul 24, 2026 | $82.59 | $82.59 | $80.275 | $80.74 | 1.64M |
Latest CYTK news
The latest Smart Investors Daily articles mentioning CYTK.
Stock researchCompany · Overview
CYTK research
Overview
Company profile and research snapshot.
Company profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $79.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 13, 2026 | Barclays | Overweight | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
Benzinga · Aug 13, 2026
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
Benzinga · Aug 13, 2026
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
